BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Chen H, Hardacre JM, Uzar A, Cameron JL, Choti MA. Isolated liver metastases from neuroendocrine tumors: Does resection prolong survival? J Am Coll Surg. 1998;187:88-92; discussion 92-3. [PMID: 9660030 DOI: 10.1016/s1072-7515(98)00099-4] [Cited by in Crossref: 258] [Cited by in F6Publishing: 84] [Article Influence: 10.8] [Reference Citation Analysis]
Number Citing Articles
1 Hüttner FJ, Schneider L, Tarantino I, Warschkow R, Schmied BM, Hackert T, Diener MK, Büchler MW, Ulrich A. Palliative resection of the primary tumor in 442 metastasized neuroendocrine tumors of the pancreas: a population-based, propensity score-matched survival analysis. Langenbecks Arch Surg. 2015;400:715-723. [PMID: 26198970 DOI: 10.1007/s00423-015-1323-x] [Cited by in Crossref: 28] [Cited by in F6Publishing: 28] [Article Influence: 4.0] [Reference Citation Analysis]
2 Pitt SC, Chen H, Kunnimalaiyaan M. Inhibition of phosphatidylinositol 3-kinase/Akt signaling suppresses tumor cell proliferation and neuroendocrine marker expression in GI carcinoid tumors. Ann Surg Oncol 2009;16:2936-42. [PMID: 19588205 DOI: 10.1245/s10434-009-0591-5] [Cited by in Crossref: 22] [Cited by in F6Publishing: 19] [Article Influence: 1.7] [Reference Citation Analysis]
3 Pan M, Yang Y, Teng T, Lu F, Chen Y, Huang H. Development and validation of a simple-to-use nomogram to predict liver metastasis in patients with pancreatic neuroendocrine neoplasms: a large cohort study. BMC Gastroenterol 2021;21:101. [PMID: 33663420 DOI: 10.1186/s12876-021-01685-w] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
4 Xiao Y, Jaskula-Sztul R, Javadi A, Xu W, Eide J, Dammalapati A, Kunnimalaiyaan M, Chen H, Gong S. Co-delivery of doxorubicin and siRNA using octreotide-conjugated gold nanorods for targeted neuroendocrine cancer therapy. Nanoscale 2012;4:7185-93. [PMID: 23070403 DOI: 10.1039/c2nr31853a] [Cited by in Crossref: 83] [Cited by in F6Publishing: 82] [Article Influence: 9.2] [Reference Citation Analysis]
5 Rubin de Celis Ferrari AC, Glasberg J, Riechelmann RP. Carcinoid syndrome: update on the pathophysiology and treatment. Clinics (Sao Paulo). 2018;73:e490s. [PMID: 30133565 DOI: 10.6061/clinics/2018/e490s] [Cited by in Crossref: 13] [Cited by in F6Publishing: 17] [Article Influence: 3.3] [Reference Citation Analysis]
6 Alistar A, Sung M, Kim M, Holcombe RF. Clinical pathways for pancreatic neuroendocrine tumors. J Gastrointest Cancer 2012;43:532-40. [PMID: 22661335 DOI: 10.1007/s12029-012-9397-y] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
7 Imamura M. Recent standardization of treatment strategy for pancreatic neuroendocrine tumors. World J Gastroenterol 2010; 16(36): 4519-4525 [PMID: 20857521 DOI: 10.3748/wjg.v16.i36.4519] [Cited by in CrossRef: 33] [Cited by in F6Publishing: 31] [Article Influence: 2.8] [Reference Citation Analysis]
8 Touzios JG, Kiely JM, Pitt SC, Rilling WS, Quebbeman EJ, Wilson SD, Pitt HA. Neuroendocrine hepatic metastases: does aggressive management improve survival? Ann Surg. 2005;241:776-783; discussion 783-785. [PMID: 15849513 DOI: 10.1097/01.sla.0000161981.58631.ab] [Cited by in Crossref: 250] [Cited by in F6Publishing: 213] [Article Influence: 14.7] [Reference Citation Analysis]
9 Alagusundaramoorthy SS, Gedaly R. Role of surgery and transplantation in the treatment of hepatic metastases from neuroendocrine tumor. World J Gastroenterol 2014; 20(39): 14348-14358 [PMID: 25339822 DOI: 10.3748/wjg.v20.i39.14348] [Cited by in CrossRef: 21] [Cited by in F6Publishing: 18] [Article Influence: 2.6] [Reference Citation Analysis]
10 Lee SY, Cheow PC, Teo JY, Ooi LL. Surgical treatment of neuroendocrine liver metastases. Int J Hepatol 2012;2012:146590. [PMID: 22319650 DOI: 10.1155/2012/146590] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 0.8] [Reference Citation Analysis]
11 Spolverato G, Bagante F, Aldrighetti L, Poultsides G, Bauer TW, Field RC, Marques HP, Weiss M, Maithel SK, Pawlik TM. Neuroendocrine Liver Metastasis: Prognostic Implications of Primary Tumor Site on Patients Undergoing Curative Intent Liver Surgery. J Gastrointest Surg 2017;21:2039-47. [PMID: 28744737 DOI: 10.1007/s11605-017-3491-1] [Cited by in Crossref: 15] [Cited by in F6Publishing: 16] [Article Influence: 3.0] [Reference Citation Analysis]
12 Bhutiani N, Bruenderman EH, Jones JM, Wehry JH, Egger ME, Philips P, Scoggins CR, McMasters KM, Martin RCG. A literature-based treatment algorithm for low-grade neuroendocrine liver metastases. HPB (Oxford) 2021;23:63-70. [PMID: 32448647 DOI: 10.1016/j.hpb.2020.04.012] [Reference Citation Analysis]
13 Greenblatt DY, Kunnimalaiyaan M, Chen H. Raf-1 activation in gastrointestinal carcinoid cells decreases tumor cell adhesion. Am J Surg 2007;193:331-5; discussion 335. [PMID: 17320529 DOI: 10.1016/j.amjsurg.2006.09.016] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.3] [Reference Citation Analysis]
14 Gedaly R, Jeon H, Johnston TD, McHugh PP, Rowland RG, Ranjan D. Surgical treatment of a rare primary renal carcinoid tumor with liver metastasis. World J Surg Oncol 2008;6:41. [PMID: 18430248 DOI: 10.1186/1477-7819-6-41] [Cited by in Crossref: 7] [Cited by in F6Publishing: 9] [Article Influence: 0.5] [Reference Citation Analysis]
15 Gundara JS, Alvarado-Bachmann R, Williams N, Gananadha S, Gill A, Hugh TJ, Samra JS. Multivisceral resection of pancreatic neuroendocrine tumours: a report of two cases. World J Surg Oncol 2011;9:93. [PMID: 21859472 DOI: 10.1186/1477-7819-9-93] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
16 Chan MY, Ma KW, Chan A. Surgical management of neuroendocrine tumor-associated liver metastases: a review. Gland Surg 2018;7:28-35. [PMID: 29629317 DOI: 10.21037/gs.2017.11.16] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 1.5] [Reference Citation Analysis]
17 Somnay Y, Simon K, Harrison AD, Kunnimalaiyaan S, Chen H, Kunnimalaiyaan M. Neuroendocrine phenotype alteration and growth suppression through apoptosis by MK-2206, an allosteric inhibitor of AKT, in carcinoid cell lines in vitro. Anticancer Drugs 2013;24:66-72. [PMID: 23147412 DOI: 10.1097/CAD.0b013e3283584f75] [Cited by in Crossref: 16] [Cited by in F6Publishing: 13] [Article Influence: 1.8] [Reference Citation Analysis]
18 Fendrich V, Bartsch DK. Surgical treatment of gastrointestinal neuroendocrine tumors. Langenbecks Arch Surg. 2011;396:299-311. [PMID: 21279821 DOI: 10.1007/s00423-011-0741-7] [Cited by in Crossref: 51] [Cited by in F6Publishing: 36] [Article Influence: 4.6] [Reference Citation Analysis]
19 Bacchetti S, Bertozzi S, Londero AP, Uzzau A, Pasqual EM. Surgical treatment and survival in patients with liver metastases from neuroendocrine tumors: a meta-analysis of observational studies. Int J Hepatol. 2013;2013:235040. [PMID: 23509630 DOI: 10.1155/2013/235040] [Cited by in Crossref: 18] [Cited by in F6Publishing: 18] [Article Influence: 2.0] [Reference Citation Analysis]
20 Sticca RP, Sticca JA. The surgeon's role in immunotherapy. Surg Oncol Clin N Am 2007;16:833-9, ix. [PMID: 18022547 DOI: 10.1016/j.soc.2007.09.001] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
21 Somnay Y, Chen H, Kunnimalaiyaan M. Synergistic effect of pasireotide and teriflunomide in carcinoids in vitro. Neuroendocrinology 2013;97:183-92. [PMID: 22965070 DOI: 10.1159/000341810] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 0.8] [Reference Citation Analysis]
22 Singla S, LeVea CM, Pokuri VK, Attwood KM, Wach MM, Tomaszewski GM, Kuvshinoff B, Iyer R. Ki67 score as a potential predictor in the selection of liver-directed therapies for metastatic neuroendocrine tumors: a single institutional experience. J Gastrointest Oncol 2016;7:441-8. [PMID: 27284478 DOI: 10.21037/jgo.2016.02.02] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 1.8] [Reference Citation Analysis]
23 Norton JA, Jensen RT. Resolved and unresolved controversies in the surgical management of patients with Zollinger-Ellison syndrome. Ann Surg. 2004;240:757-773. [PMID: 15492556 DOI: 10.1097/01.sla.0000143252.02142.3e] [Cited by in Crossref: 166] [Cited by in F6Publishing: 140] [Article Influence: 9.2] [Reference Citation Analysis]
24 Imamura M, Komoto I, Ota S. Changing treatment strategy for gastrinoma in patients with Zollinger-Ellison syndrome. World J Surg. 2006;30:1-11. [PMID: 16369713 DOI: 10.1007/s00268-005-0341-1] [Cited by in Crossref: 54] [Cited by in F6Publishing: 36] [Article Influence: 3.4] [Reference Citation Analysis]
25 Chen H. Life-long Lessons Learned From John Cameron in 7 Words. Ann Surg 2018;267:S13-5. [PMID: 28885504 DOI: 10.1097/SLA.0000000000002515] [Reference Citation Analysis]
26 McKenna LR, Edil BH. Update on pancreatic neuroendocrine tumors. Gland Surg. 2014;3:258-275. [PMID: 25493258 DOI: 10.3978/j.issn.2227-684x.2014.06.03] [Cited by in F6Publishing: 25] [Reference Citation Analysis]
27 Jang S, Jin H, Roy M, Ma AL, Gong S, Jaskula-Sztul R, Chen H. Antineoplastic effects of histone deacetylase inhibitors in neuroendocrine cancer cells are mediated through transcriptional regulation of Notch1 by activator protein 1. Cancer Med 2017;6:2142-52. [PMID: 28776955 DOI: 10.1002/cam4.1151] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 1.2] [Reference Citation Analysis]
28 Carter AM, Kumar N, Herring B, Tan C, Guenter R, Telange R, Howse W, Viol F, McCaw TR, Bickerton HH, Gupta P, Gillardon F, Woltering EA, Dhall D, Totenhagen J, Banerjee RR, Kurian EM, Reddy S, Chen H, Schrader J, Bart Rose J, Mukhtar MS, Bibb JA. Cdk5 drives formation of heterogeneous pancreatic neuroendocrine tumors. Oncogenesis 2021;10:83. [PMID: 34862365 DOI: 10.1038/s41389-021-00372-5] [Reference Citation Analysis]
29 Kondo NI, Ikeda Y. Practical management and treatment of pancreatic neuroendocrine tumors. Gland Surg. 2014;3:276-283. [PMID: 25493259 DOI: 10.3978/j.issn.2227-684x.2013.12.05] [Cited by in F6Publishing: 4] [Reference Citation Analysis]
30 Lewis MA, Hubbard J. Multimodal liver-directed management of neuroendocrine hepatic metastases. Int J Hepatol. 2011;2011:452343. [PMID: 22121491 DOI: 10.4061/2011/452343] [Cited by in Crossref: 17] [Cited by in F6Publishing: 11] [Article Influence: 1.5] [Reference Citation Analysis]
31 Jin M, Zhou X, Yearsley M, Frankel WL. Liver Metastases of Neuroendocrine Tumors Rarely Show Overlapping Immunoprofile with Hepatocellular Carcinomas. Endocr Pathol 2016;27:253-8. [PMID: 27300354 DOI: 10.1007/s12022-016-9442-7] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.4] [Reference Citation Analysis]
32 Yu X, Gu J, Wu H, Fu D, Li J, Jin C. Resection of Liver Metastases: A Treatment Provides a Long-Term Survival Benefit for Patients with Advanced Pancreatic Neuroendocrine Tumors: A Systematic Review and Meta-Analysis. J Oncol. 2018;2018:6273947. [PMID: 30538745 DOI: 10.1155/2018/6273947] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
33 Lee E, Leon Pachter H, Sarpel U. Hepatic arterial embolization for the treatment of metastatic neuroendocrine tumors. Int J Hepatol. 2012;2012:471203. [PMID: 22319651 DOI: 10.1155/2012/471203] [Cited by in Crossref: 16] [Cited by in F6Publishing: 12] [Article Influence: 1.6] [Reference Citation Analysis]
34 Deguelte S, Perrier M, Hammoutene C, Cadiot G, Kianmanesh R. Surgery and Perioperative Management in Small Intestinal Neuroendocrine Tumors. J Clin Med. 2020;9. [PMID: 32708330 DOI: 10.3390/jcm9072319] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
35 Musholt TJ, Lang H. [Indications and operative procedures for neuroendocrine liver metastases]. Chirurg 2009;80:113-21. [PMID: 19212693 DOI: 10.1007/s00104-008-1614-7] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
36 Pinchot SN, Adler JT, Luo Y, Ju J, Li W, Shen B, Kunnimalaiyaan M, Chen H. Tautomycin suppresses growth and neuroendocrine hormone markers in carcinoid cells through activation of the Raf-1 pathway. Am J Surg 2009;197:313-9. [PMID: 19245907 DOI: 10.1016/j.amjsurg.2008.10.007] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 0.8] [Reference Citation Analysis]
37 Fendrich V, Michl P, Habbe N, Bartsch DK. Liver-specific therapies for metastases of neuroendocrine pancreatic tumors. World J Hepatol 2010; 2(10): 367-373 [PMID: 21160945 DOI: 10.4254/wjh.v2.i10.367] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 0.9] [Reference Citation Analysis]
38 Sher LS, Levi DM, Wecsler JS, Lo M, Petrovic LM, Groshen S, Ji L, Uso TD, Tector AJ, Hamilton AS, Marsh JW, Schwartz ME. Liver transplantation for metastatic neuroendocrine tumors: Outcomes and prognostic variables. J Surg Oncol 2015;112:125-32. [PMID: 26171686 DOI: 10.1002/jso.23973] [Cited by in Crossref: 16] [Cited by in F6Publishing: 13] [Article Influence: 2.3] [Reference Citation Analysis]
39 Roland CL, Bian A, Mansour JC, Yopp AC, Balch GC, Sharma R, Xie XJ, Schwarz RE. Survival impact of malignant pancreatic neuroendocrine and islet cell neoplasm phenotypes. J Surg Oncol 2012;105:595-600. [PMID: 22006521 DOI: 10.1002/jso.22118] [Cited by in Crossref: 21] [Cited by in F6Publishing: 18] [Article Influence: 1.9] [Reference Citation Analysis]
40 Mayo SC, Herman JM, Cosgrove D, Bhagat N, Kamel I, Geschwind JF, Pawlik TM. Emerging approaches in the management of patients with neuroendocrine liver metastasis: role of liver-directed and systemic therapies. J Am Coll Surg 2013;216:123-34. [PMID: 23063263 DOI: 10.1016/j.jamcollsurg.2012.08.027] [Cited by in Crossref: 50] [Cited by in F6Publishing: 39] [Article Influence: 5.0] [Reference Citation Analysis]
41 Shrikhande SV, Sirohi B, Goel M, Barreto SG. Pancreatic neuroendocrine tumors. Indian J Gastroenterol 2013;32:3-17. [PMID: 23054950 DOI: 10.1007/s12664-012-0257-2] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
42 Hofland J, Kaltsas G, de Herder WW. Advances in the Diagnosis and Management of Well-Differentiated Neuroendocrine Neoplasms. Endocr Rev. 2020;41. [PMID: 31555796 DOI: 10.1210/endrev/bnz004] [Cited by in Crossref: 28] [Cited by in F6Publishing: 27] [Article Influence: 28.0] [Reference Citation Analysis]
43 Van Gompel JJ, Sippel RS, Warner TF, Chen H. Gastrointestinal carcinoid tumors: factors that predict outcome. World J Surg. 2004;28:387-392. [PMID: 14994141 DOI: 10.1007/s00268-003-7019-3] [Cited by in Crossref: 52] [Cited by in F6Publishing: 52] [Article Influence: 2.9] [Reference Citation Analysis]
44 Barreto SG, Shukla PJ, Shrikhande SV. Tumors of the Pancreatic Body and Tail. World J Oncol. 2010;1:52-65. [PMID: 29147182 DOI: 10.4021/wjon2010.04.200w] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 0.3] [Reference Citation Analysis]
45 Reddy SK, Kesmodel SB, Alexander HR. Isolated hepatic perfusion for patients with liver metastases. Ther Adv Med Oncol. 2014;6:180-194. [PMID: 25057304 DOI: 10.1177/1758834014529175] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 1.3] [Reference Citation Analysis]
46 Truong M, Cook MR, Pinchot SN, Kunnimalaiyaan M, Chen H. Resveratrol induces Notch2-mediated apoptosis and suppression of neuroendocrine markers in medullary thyroid cancer. Ann Surg Oncol 2011;18:1506-11. [PMID: 21184191 DOI: 10.1245/s10434-010-1488-z] [Cited by in Crossref: 29] [Cited by in F6Publishing: 28] [Article Influence: 2.4] [Reference Citation Analysis]
47 Nigri G, Petrucciani N, Debs T, Mangogna LM, Crovetto A, Moschetta G, Persechino R, Aurello P, Ramacciato G. Treatment options for PNET liver metastases: a systematic review. World J Surg Oncol. 2018;16:142. [PMID: 30007406 DOI: 10.1186/s12957-018-1446-y] [Cited by in Crossref: 16] [Cited by in F6Publishing: 14] [Article Influence: 4.0] [Reference Citation Analysis]
48 Boudreaux JP, Putty B, Frey DJ, Woltering E, Anthony L, Daly I, Ramcharan T, Lopera J, Castaneda W. Surgical treatment of advanced-stage carcinoid tumors: lessons learned. Ann Surg 2005;241:839-45; discussion 845-6. [PMID: 15912033 DOI: 10.1097/01.sla.0000164073.08093.5d] [Cited by in Crossref: 92] [Cited by in F6Publishing: 81] [Article Influence: 5.4] [Reference Citation Analysis]
49 Bacchetti S, Pasqual EM, Bertozzi S, Londero AP, Risaliti A. Curative versus palliative surgical resection of liver metastases in patients with neuroendocrine tumors: a meta-analysis of observational studies. Gland Surg. 2014;3:243-251. [PMID: 25493256 DOI: 10.3978/j.issn.2227-684x.2014.02.05] [Cited by in F6Publishing: 4] [Reference Citation Analysis]
50 Lee RC, Kanhere H, Trochsler M, Broadbridge V, Maddern G, Price TJ. Pancreatic, periampullary and biliary cancer with liver metastases: Should we consider resection in selected cases? World J Gastrointest Oncol 2018; 10(8): 211-220 [PMID: 30147847 DOI: 10.4251/wjgo.v10.i8.211] [Cited by in CrossRef: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
51 Williamson JM, Thorn CC, Spalding D, Williamson RC. Pancreatic and peripancreatic somatostatinomas. Ann R Coll Surg Engl 2011;93:356-60. [PMID: 21943457 DOI: 10.1308/003588411X582681] [Cited by in Crossref: 17] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
52 Eghtesad B, Aucejo F. Liver transplantation for malignancies. J Gastrointest Cancer. 2014;45:353-362. [PMID: 24604263 DOI: 10.1007/s12029-014-9590-2] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 1.7] [Reference Citation Analysis]
53 Haugvik SP, Labori KJ, Edwin B, Mathisen Ø, Gladhaug IP. Surgical treatment of sporadic pancreatic neuroendocrine tumors: a state of the art review. ScientificWorldJournal. 2012;2012:357475. [PMID: 23304085 DOI: 10.1100/2012/357475] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 1.2] [Reference Citation Analysis]
54 Zlate AC, Alexandrescu ST, Grigorie RT, Gramaticu IM, Kraft A, Dumitru R, Tomescu D, Popescu I. THE ROLE OF SURGERY IN A PATIENT WITH CARCINOID SYNDROME, COMPLICATED BY CARCINOID HEART DISEASE. Acta Endocrinol (Buchar) 2018;14:117-21. [PMID: 31149245 DOI: 10.4183/aeb.2018.117] [Reference Citation Analysis]
55 Tsoli M, Chatzellis E, Koumarianou A, Kolomodi D, Kaltsas G. Current best practice in the management of neuroendocrine tumors. Ther Adv Endocrinol Metab. 2019;10:2042018818804698. [PMID: 30800264 DOI: 10.1177/2042018818804698] [Cited by in Crossref: 15] [Cited by in F6Publishing: 17] [Article Influence: 3.8] [Reference Citation Analysis]
56 Wang R, Zheng-Pywell R, Chen HA, Bibb JA, Chen H, Rose JB. Management of Gastrointestinal Neuroendocrine Tumors. Clin Med Insights Endocrinol Diabetes. 2019;12:1179551419884058. [PMID: 31695546 DOI: 10.1177/1179551419884058] [Cited by in Crossref: 16] [Cited by in F6Publishing: 14] [Article Influence: 5.3] [Reference Citation Analysis]
57 Fiore F, Del Prete M, Franco R, Marotta V, Ramundo V, Marciello F, Di Sarno A, Carratù AC, de Luca di Roseto C, Colao A, Faggiano A. Transarterial embolization (TAE) is equally effective and slightly safer than transarterial chemoembolization (TACE) to manage liver metastases in neuroendocrine tumors. Endocrine 2014;47:177-82. [DOI: 10.1007/s12020-013-0130-9] [Cited by in Crossref: 65] [Cited by in F6Publishing: 61] [Article Influence: 8.1] [Reference Citation Analysis]
58 Schell SR, Camp ER, Caridi JG, Hawkins IF Jr. Hepatic artery embolization for control of symptoms, octreotide requirements, and tumor progression in metastatic carcinoid tumors. J Gastrointest Surg 2002;6:664-70. [PMID: 12399054 DOI: 10.1016/s1091-255x(02)00044-6] [Cited by in Crossref: 50] [Cited by in F6Publishing: 14] [Article Influence: 2.6] [Reference Citation Analysis]
59 Chen JY, Cook MR, Pinchot SN, Kunnimalaiyaan M, Chen H. MG-132 inhibits carcinoid growth and alters the neuroendocrine phenotype. J Surg Res. 2010;158:15-19. [PMID: 19765735 DOI: 10.1016/j.jss.2009.05.032] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 0.8] [Reference Citation Analysis]
60 Ramage JK, Ahmed A, Ardill J, Bax N, Breen DJ, Caplin ME, Corrie P, Davar J, Davies AH, Lewington V, Meyer T, Newell-Price J, Poston G, Reed N, Rockall A, Steward W, Thakker RV, Toubanakis C, Valle J, Verbeke C, Grossman AB;  UK and Ireland Neuroendocrine Tumour Society. Guidelines for the management of gastroenteropancreatic neuroendocrine (including carcinoid) tumours (NETs). Gut. 2012;61:6-32. [PMID: 22052063 DOI: 10.1136/gutjnl-2011-300831] [Cited by in Crossref: 353] [Cited by in F6Publishing: 280] [Article Influence: 32.1] [Reference Citation Analysis]
61 Lesurtel M, Nagorney DM, Mazzaferro V, Jensen RT, Poston GJ. When should a liver resection be performed in patients with liver metastases from neuroendocrine tumours? A systematic review with practice recommendations. HPB (Oxford). 2015;17:17-22. [PMID: 24636662 DOI: 10.1111/hpb.12225] [Cited by in Crossref: 33] [Cited by in F6Publishing: 31] [Article Influence: 4.1] [Reference Citation Analysis]
62 Busquets J, Ramírez-Maldonado E, Serrano T, Peláez N, Secanella L, Ruiz-Osuna S, Ramos E, Lladó L, Fabregat J. Surgical treatment of non-functioning pancreatic neuroendocrine tumours based on three clinical scenarios. Cir Esp 2016;94:578-87. [PMID: 27863693 DOI: 10.1016/j.ciresp.2016.07.008] [Reference Citation Analysis]
63 Kaçmaz E, Heidsma CM, Besselink MGH, Dreijerink KMA, Klümpen HJ, Nieveen van Dijkum EJM, Engelsman AF. Treatment of Liver Metastases from Midgut Neuroendocrine Tumours: A Systematic Review and Meta-Analysis. J Clin Med 2019;8:E403. [PMID: 30909512 DOI: 10.3390/jcm8030403] [Cited by in Crossref: 9] [Cited by in F6Publishing: 12] [Article Influence: 3.0] [Reference Citation Analysis]
64 Frilling A, Sotiropoulos GC, Li J, Kornasiewicz O, Plöckinger U. Multimodal management of neuroendocrine liver metastases. HPB (Oxford). 2010;12:361-379. [PMID: 20662787 DOI: 10.1111/j.1477-2574.2010.00175.x] [Cited by in Crossref: 94] [Cited by in F6Publishing: 78] [Article Influence: 8.5] [Reference Citation Analysis]
65 Somnay YR, Dull BZ, Eide J, Jaskula-Sztul R, Chen H. Chrysin suppresses achaete-scute complex-like 1 and alters the neuroendocrine phenotype of carcinoids. Cancer Gene Ther 2015;22:496-505. [PMID: 26403073 DOI: 10.1038/cgt.2015.49] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.7] [Reference Citation Analysis]
66 Saeed A, Buell JF, Kandil E. Surgical treatment of liver metastases in patients with neuroendocrine tumors. Ann Transl Med 2013;1:6. [PMID: 25332951 DOI: 10.3978/j.issn.2305-5839.2013.01.08] [Cited by in F6Publishing: 7] [Reference Citation Analysis]
67 Oh TG, Chung MJ, Park JY, Bang SM, Park SW, Chung JB, Song SY. Prognostic factors and characteristics of pancreatic neuroendocrine tumors: single center experience. Yonsei Med J 2012;53:944-51. [PMID: 22869477 DOI: 10.3349/ymj.2012.53.5.944] [Cited by in Crossref: 11] [Cited by in F6Publishing: 14] [Article Influence: 1.2] [Reference Citation Analysis]
68 Watzka FM, Fottner C, Miederer M, Schad A, Weber MM, Otto G, Lang H, Musholt TJ. Surgical therapy of neuroendocrine neoplasm with hepatic metastasis: patient selection and prognosis. Langenbecks Arch Surg. 2015;400:349-358. [PMID: 25682055 DOI: 10.1007/s00423-015-1277-z] [Cited by in Crossref: 26] [Cited by in F6Publishing: 27] [Article Influence: 3.7] [Reference Citation Analysis]
69 Wells SA, Hinshaw JL, Lubner MG, Ziemlewicz TJ, Brace CL, Lee FT Jr. Liver Ablation: Best Practice. Radiol Clin North Am 2015;53:933-71. [PMID: 26321447 DOI: 10.1016/j.rcl.2015.05.012] [Cited by in Crossref: 43] [Cited by in F6Publishing: 38] [Article Influence: 6.1] [Reference Citation Analysis]
70 Wilson HM. Chronic subacute bowel obstruction caused by carcinoid tumour misdiagnosed as irritable bowel syndrome: a case report. Cases J 2009;2:78. [PMID: 19161610 DOI: 10.1186/1757-1626-2-78] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.3] [Reference Citation Analysis]
71 Chen H, George BD, Kaufman HS, Malaki MB, Mortensen NJ, Kettlewell MG. Endoscopic transanal resection provides palliation equivalent to transabdominal resection in patients with metastatic rectal cancer. J Gastrointest Surg. 2001;5:282-286. [PMID: 11360051 DOI: 10.1016/s1091-255x(01)80049-4] [Cited by in Crossref: 11] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
72 Sener SF. Results of surgical resection for metastatic liver tumors. Cancer Treat Res 2001;109:207-17. [PMID: 11775437 DOI: 10.1007/978-1-4757-3371-6_11] [Reference Citation Analysis]
73 Pitt SC, Knuth J, Keily JM, McDermott JC, Weber SM, Chen H, Rilling WS, Quebbeman EJ, Agarwal DM, Pitt HA. Hepatic neuroendocrine metastases: chemo- or bland embolization? J Gastrointest Surg. 2008;12:1951-1960. [PMID: 18709512 DOI: 10.1007/s11605-008-0640-6] [Cited by in Crossref: 75] [Cited by in F6Publishing: 62] [Article Influence: 5.4] [Reference Citation Analysis]
74 Kuei A, Saab S, Cho SK, Kee ST, Lee EW. Effects of Yttrium-90 selective internal radiation therapy on non-conventional liver tumors. World J Gastroenterol 2015; 21(27): 8271-8283 [PMID: 26217079 DOI: 10.3748/wjg.v21.i27.8271] [Cited by in CrossRef: 25] [Cited by in F6Publishing: 20] [Article Influence: 3.6] [Reference Citation Analysis]
75 Shao QQ, Zhao BB, Dong LB, Cao HT, Wang WB. Surgical management of Zollinger-Ellison syndrome: Classical considerations and current controversies. World J Gastroenterol 2019; 25(32): 4673-4681 [PMID: 31528093 DOI: 10.3748/wjg.v25.i32.4673] [Cited by in CrossRef: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
76 House MG, Cameron JL, Lillemoe KD, Schulick RD, Choti MA, Hansel DE, Hruban RH, Maitra A, Yeo CJ. Differences in survival for patients with resectable versus unresectable metastases from pancreatic islet cell cancer. J Gastrointest Surg. 2006;10:138-145. [PMID: 16368504 DOI: 10.1016/j.gassur.2005.05.004] [Cited by in Crossref: 55] [Cited by in F6Publishing: 45] [Article Influence: 3.4] [Reference Citation Analysis]
77 Si Y, Kim S, Ou J, Lu Y, Ernst P, Chen K, Whitt J, Carter AM, Markert JM, Bibb JA, Chen H, Zhou L, Jaskula-Sztul R, Liu XM. Anti-SSTR2 antibody-drug conjugate for neuroendocrine tumor therapy. Cancer Gene Ther 2021;28:799-812. [PMID: 32684623 DOI: 10.1038/s41417-020-0196-5] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 5.0] [Reference Citation Analysis]
78 Kawasaki K, Kawaguchi Y, Suzuki Y, Tanaka N. Renal neuroendocrine tumour and synchronous pancreas metastasis: histopathological diagnosis using prostatic acid phosphatase. BMJ Case Rep 2016;2016:bcr2016214759. [PMID: 27803081 DOI: 10.1136/bcr-2016-214759] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
79 Chen H, Merchant NB, Didolkar MS. Hepatic resection using intermittent vascular inflow occlusion and low central venous pressure anesthesia improves morbidity and mortality. J Gastrointest Surg. 2000;4:162-167. [PMID: 10675239 DOI: 10.1016/s1091-255x(00)80052-9] [Cited by in Crossref: 92] [Cited by in F6Publishing: 22] [Article Influence: 4.2] [Reference Citation Analysis]
80 Cook MR, Pinchot SN, Jaskula-Sztul R, Luo J, Kunnimalaiyaan M, Chen H. Identification of a novel Raf-1 pathway activator that inhibits gastrointestinal carcinoid cell growth. Mol Cancer Ther. 2010;9:429-437. [PMID: 20103603 DOI: 10.1158/1535-7163.MCT-09-0718] [Cited by in Crossref: 24] [Cited by in F6Publishing: 15] [Article Influence: 2.0] [Reference Citation Analysis]
81 Gomez D, Malik HZ, Al-Mukthar A, Menon KV, Toogood GJ, Lodge JP, Prasad KR. Hepatic resection for metastatic gastrointestinal and pancreatic neuroendocrine tumours: outcome and prognostic predictors. HPB (Oxford) 2007;9:345-51. [PMID: 18345317 DOI: 10.1080/13651820701504199] [Cited by in Crossref: 34] [Cited by in F6Publishing: 27] [Article Influence: 2.8] [Reference Citation Analysis]
82 Palesty JA, Al-Kasspooles M, Gibbs JF. Patient selection for surgical management of primary and metastatic liver cancers: current perspectives. Semin Intervent Radiol 2006;23:13-20. [PMID: 21326716 DOI: 10.1055/s-2006-939837] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
83 Macedo D, Amaral T, Fernandes I, Sousa AR, Costa AL, Távora I, Quintela A, Cortes P, Costa L. The Treatment of Liver Metastases in Patients with Neuroendocrine Tumors in 2012. ISRN Hepatol 2013;2013:702167. [PMID: 27335831 DOI: 10.1155/2013/702167] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
84 Veenendaal LM, Borel Rinkes IH, Lips CJ, van Hillegersberg R. Liver metastases of neuroendocrine tumours; early reduction of tumour load to improve life expectancy. World J Surg Oncol 2006;4:35. [PMID: 16800893 DOI: 10.1186/1477-7819-4-35] [Cited by in Crossref: 33] [Cited by in F6Publishing: 29] [Article Influence: 2.1] [Reference Citation Analysis]
85 Fendrich V, Langer P, Celik I, Bartsch DK, Zielke A, Ramaswamy A, Rothmund M. An aggressive surgical approach leads to long-term survival in patients with pancreatic endocrine tumors. Ann Surg. 2006;244:845-851; discussion 852-853. [PMID: 17122609 DOI: 10.1097/01.sla.0000246951.21252.60] [Cited by in Crossref: 114] [Cited by in F6Publishing: 92] [Article Influence: 7.6] [Reference Citation Analysis]
86 Hung JS, Chang MC, Lee PH, Tien YW. Is surgery indicated for patients with symptomatic nonfunctioning pancreatic neuroendocrine tumor and unresectable hepatic metastases? World J Surg. 2007;31:2392-2397. [PMID: 17960455 DOI: 10.1007/s00268-007-9264-3] [Cited by in Crossref: 19] [Cited by in F6Publishing: 14] [Article Influence: 1.4] [Reference Citation Analysis]
87 Ramage JK, Davies AH, Ardill J, Bax N, Caplin M, Grossman A, Hawkins R, McNicol AM, Reed N, Sutton R. Guidelines for the management of gastroenteropancreatic neuroendocrine (including carcinoid) tumours. Gut. 2005;54 Suppl 4:iv1-i16. [PMID: 15888809 DOI: 10.1136/gut.2004.053314] [Cited by in Crossref: 173] [Cited by in F6Publishing: 192] [Article Influence: 10.2] [Reference Citation Analysis]
88 Chen G, Jaskula-Sztul R, Esquibel CR, Lou I, Zheng Q, Dammalapati A, Harrison A, Eliceiri KW, Tang W, Chen H, Gong S. Neuroendocrine Tumor-Targeted Upconversion Nanoparticle-Based Micelles for Simultaneous NIR-Controlled Combination Chemotherapy and Photodynamic Therapy, and Fluorescence Imaging. Adv Funct Mater 2017;27:1604671. [PMID: 28989337 DOI: 10.1002/adfm.201604671] [Cited by in Crossref: 97] [Cited by in F6Publishing: 98] [Article Influence: 19.4] [Reference Citation Analysis]
89 Ambe CM, Nguyen P, Centeno BA, Choi J, Strosberg J, Kvols L, Hodul P, Hoffe S, Malafa MP. Multimodality Management of "Borderline Resectable" Pancreatic Neuroendocrine Tumors: Report of a Single-Institution Experience. Cancer Control. 2017;24:1073274817729076. [PMID: 28975822 DOI: 10.1177/1073274817729076] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 2.5] [Reference Citation Analysis]
90 Sistani G, Sutherland DEK, Mujoomdar A, Wiseman DP, Khatami A, Tsvetkova E, Reid RH, Laidley DT. Efficacy of 177Lu-Dotatate Induction and Maintenance Therapy of Various Types of Neuroendocrine Tumors: A Phase II Registry Study. Curr Oncol 2020;28:115-27. [PMID: 33622997 DOI: 10.3390/curroncol28010015] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
91 Fendrich V, Waldmann J, Bartsch DK, Langer P. Surgical management of pancreatic endocrine tumors. Nat Rev Clin Oncol 2009;6:419-28. [DOI: 10.1038/nrclinonc.2009.82] [Cited by in Crossref: 81] [Cited by in F6Publishing: 62] [Article Influence: 6.2] [Reference Citation Analysis]